|
Jul 21, 2021
|
Dynavax to Report Second Quarter 2021 Financial Results and Host Conference Call on August 4, 2021
|
|
|
Jul 06, 2021
|
Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate
|
|
|
Jul 02, 2021
|
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Jun 30, 2021
|
Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate
|
|
|
Jun 29, 2021
|
Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Jun 09, 2021
|
Dynavax to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
|
|
|
May 27, 2021
|
Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany
|
|
|
May 19, 2021
|
Dynavax to Present at the William Blair 41st Annual Growth Stock Conference
|
|
|
May 11, 2021
|
Dynavax Announces Pricing of $200 Million Convertible Senior Notes Offering
|
|
|
May 10, 2021
|
Dynavax Announces Proposed Private Offering of $200 Million of Convertible Senior Notes
|
|
